Combination of | |
---|---|
Bazedoxifene | Selective estrogen receptor modulator |
Conjugated estrogens | Estrogen |
Clinical data | |
Trade names | Duavee, Duavive |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a614004 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG |
Bazedoxifene/conjugated estrogens, sold under the brand name Duavee in the US and Duavive in the EU, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis.[4][5][6] It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens. It is taken by mouth.
The combination was approved for medical use in the United States in October 2013,[7] and in the European Union in December 2014.[3]